IBSA Pharma: what changed
Position among the sector peers
Sector benchmark: create a free account or sign in to use this tool.
You see every sector peer as a dot per ratio, with the company in two financial years and every ratio over five years against the sector.
What moved between 2024 and 2025
Largest movements
- Cash -€11,057
down €11,057 (-34.9%), from €31,653 to €20,597
mainly Tax, wage and social debts (-€16,908) and Trade debts (-€3,457)
- Receivables within one year -€7,365
down €7,365 (-12.9%), from €56,953 to €49,588
of which Other amounts receivable: -€11,470
- Tax, wage and social debts -€16,908
down €16,908 (-35.7%), from €47,306 to €30,398
of which Taxes: -€8,871
- Trade debts -€3,457
down €3,457 (-34.8%), from €9,939 to €6,482
- Profit (loss) carried forward +€1,299
up €1,299 (+15.2%), from €8,554 to €9,853
- Gross operating margin -€65,352
down €65,352 (-20.6%), from €317,984 to €252,632
- Staff costs -€63,561
down €63,561 (-21.4%), from €296,979 to €233,418
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €90,799 | €71,733 | -€19,067 | -21.0% |
| Current assets | 29/58 | €90,799 | €71,733 | -€19,067 | -21.0% |
| Amounts receivable within one year | 40/41 | €56,953 | €49,588 | -€7,365 | -12.9% |
| Trade receivables | 40 | €43,900 | €48,005 | +€4,105 | +9.4% |
| Other amounts receivable | 41 | €13,053 | €1,583 | -€11,470 | -87.9% |
| Cash at bank and in hand | 54/58 | €31,653 | €20,597 | -€11,057 | -34.9% |
| Deferred charges and accrued income | 490/1 | €2,193 | €1,548 | -€645 | -29.4% |
| Total equity and liabilities | 10/49 | €90,799 | €71,733 | -€19,067 | -21.0% |
| Equity | 10/15 | €33,554 | €34,853 | +€1,299 | +3.9% |
| Contributions | 10/11 | €25,000 | €25,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €8,554 | €9,853 | +€1,299 | +15.2% |
| Amounts payable | 17/49 | €57,245 | €36,880 | -€20,366 | -35.6% |
| Amounts payable within one year | 42/48 | €57,245 | €36,880 | -€20,366 | -35.6% |
| Trade debts | 44 | €9,939 | €6,482 | -€3,457 | -34.8% |
| Suppliers | 440/4 | €9,939 | €6,482 | -€3,457 | -34.8% |
| Taxes, remuneration and social security | 45 | €47,306 | €30,398 | -€16,908 | -35.7% |
| Taxes | 450/3 | €24,674 | €15,802 | -€8,871 | -36.0% |
| Remuneration and social security | 454/9 | €22,633 | €14,596 | -€8,037 | -35.5% |
| Remuneration, social security and pensions | 62 | €296,979 | €233,418 | -€63,561 | -21.4% |
| Other operating charges | 640/8 | - | €465 | +€465 | |
| Gross operating margin | 9900 | €317,984 | €252,632 | -€65,352 | -20.6% |
| Operating profit (loss) | 9901 | €21,006 | €18,750 | -€2,256 | -10.7% |
| Financial income | 75/76B | €1 | €0 | -€1 | -100% |
| Recurring financial income | 75 | €1 | €0 | -€1 | -100% |
| Financial charges | 65/66B | €7,016 | €6,759 | -€257 | -3.7% |
| Recurring financial charges | 65 | €7,016 | €6,759 | -€257 | -3.7% |
| Profit (loss) for the period before taxes | 9903 | €13,990 | €11,991 | -€1,999 | -14.3% |
| Income taxes | 67/77 | €7,875 | €10,692 | +€2,817 | +35.8% |
| Profit (loss) for the period | 9904 | €6,116 | €1,299 | -€4,817 | -78.8% |
| Profit (loss) for the period to be appropriated | 9905 | €6,116 | €1,299 | -€4,817 | -78.8% |
Value
latest balance sheet 31-12-2025 · indication, not a valuation or adviceIndicative value of the equity
Indication, not a valuation or adviceMidpoint €31,110 · 50% capitalised earnings, 50% adjusted equity
Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50% revaluation €0 other adjustment €0 EBITDA multiple
The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.
Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.
Adjusted equity
- Equity (10/15)
- €34,853
- Formation expenses (20)
- €0
- Intangible fixed assets (21)
- €0
- Revaluation of assets
- €0
- Deferred tax on the revaluation
- €0
- Other adjustment
- €0
- Adjusted equity
- €34,853
Capitalised earnings
- 2025
- €1,299
- 2024
- €6,116
- 2023
- €2,438
- Average result, excluding non-recurring income and charges
- €3,284
- Divided by the capitalisation rate
- 14% / 12% / 10%
- Capitalised earnings
- €23,457 / €27,367 / €32,840
Your EBITDA multiple
- EBITDA 2025
- -
- Net financial debt
- -€20,597
- Your multiple
- -
- Value with your multiple
- -
These accounts do not break down the debts after one year. They count in full as financial debt.
Limits of the indication
- Checked holds no market prices or comparable transactions.
- Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
- Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
- The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.
For a valuation to base a decision on, go to a company auditor or a certified accountant.
Next steps
Calculation and sources
Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 9 November 2026 via checked.be.